NCT05652192View on ClinicalTrials.gov

SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Nasopharyngeal Carcinoma
Interventions
RADIATION

SBRT

SBRT was added to systematic treatment (chemo+ PD-1 antibody)

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER